In conclusion, we demonstrate differences in chromatin response to RA in neuroblastoma according to type of ATRX alteration and propose that within the ATRX subgroup, there is likely to be significant heterogeneity in response to differentiation therapies depending on the precise type of alteration. The gene discussed is ATRX; the disease is neuroblastoma.